Genomics-based drug innovation: visions and commercial viability
by Alison Kraft, Harry Rothman
International Journal of Biotechnology (IJBT), Vol. 10, No. 5, 2008

Abstract: This paper tracks the development of genomics between 1990 and 2005 principally within the US context and reviews that development with specific respect to early expectations of genomics-based pharmaceutical innovation, the initial claims made for it, and the realities of its current position. Emphasis is placed on relations between the genomics sector and its larger pharmaceutical and biotechnology counterparts, and to the financial markets on which drug innovation ultimately rests. The analysis combines historical and sociological approaches to the study of innovation, and situates genomics within the wider context of the commercialisation of the life sciences. In particular, we highlight and reflect critically on the disparity between the expectations and 'hype' surrounding genomics, and assess its impact, to date, on pharmaceutical innovation.

Online publication date: Tue, 18-Nov-2008

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com